Scilex Holding Co
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
SCLX$1.61-7.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except for net loss per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Net revenue | $7,642 | $9,896 | $16,255 | $14,900 |
| Operating costs and expenses: | ||||
| Cost of revenue | 3,677 | 3,272 | 8,124 | 4,656 |
| Research and development | 3,336 | 6,187 | 6,546 | 8,643 |
| Selling, general and administrative | 27,960 | 19,841 | 58,993 | 47,901 |
| Intangible amortization | 2,092 | 1,008 | 4,184 | 2,010 |
| Legal settlements | — | 95 | — | 95 |
| Total operating costs and expenses | 37,065 | 30,403 | 77,847 | 63,305 |
| Loss from operations | (29,423) | (20,507) | (61,592) | (48,405) |
| Other (income) expense, net: | ||||
| (Gain) loss on derivative liability | 6,644 | 12,375 | (19,065) | 1,966 |
| Loss on compound derivative of Scilex-St. James Loans | 6,930 | — | 28,759 | — |
| Change in fair value of debt and liability instruments | 232 | 8,366 | 3,029 | 14,480 |
| Loss on foreign currency exchange | 150 | 99 | 429 | 95 |
| Unrealized loss on digital assets, net | 9,258 | — | 27,322 | — |
| Unrealized loss on equity method investments carried at fair value, net | 50,737 | — | 82,447 | — |
| Realized (gain) loss on equity method investments carried at fair value, net | 5,254 | — | (37,084) | — |
| Realized (gain) loss on securities | (5) | — | 3,066 | — |
| Interest Expense | 6,104 | 2,682 | 11,560 | 5,163 |
| Other (income) expense, net | 252 | — | (1,426) | — |
| Total other expense | 85,556 | 23,522 | 99,037 | 21,704 |
| Loss before income taxes | (114,979) | (44,029) | (160,629) | (70,109) |
| Income tax expense | 7 | 19 | 7 | 19 |
| Net loss | (114,986) | (44,048) | (160,636) | (70,128) |
| Net loss attributable to noncontrolling interests | (1,486) | (1,740) | (3,866) | (1,740) |
| Net loss attributable to common stockholders before deemed dividend | (113,500) | (42,308) | (156,770) | (68,388) |
| Deemed dividend | (1,229) | (43,753) | (1,229) | (43,753) |
| Net loss attributable to common stockholders | $(114,729) | $(86,061) | $(157,999) | $(112,141) |
| Loss per share attributable to common stockholders — basic & diluted | $(16.65) | $(7.42) | $(22.93) | $(9.68) |
| Weighted average number of shares during the period — basic & diluted | 6,892 | 11,595 | 6,891 | 11,580 |
| Comprehensive loss: | ||||
| Net loss | $(114,986) | $(44,048) | $(160,636) | $(70,128) |
| Other comprehensive loss: | ||||
| Foreign currency translation adjustment | (432) | — | (1,179) | — |
| Total other comprehensive loss | (432) | — | (1,179) | — |
| Comprehensive Loss | (115,418) | (44,048) | (161,815) | (70,128) |
| Less: Comprehensive loss attributable to noncontrolling interests | (1,486) | (1,740) | (3,866) | (1,740) |
| Comprehensive loss attributable to common stockholders before deemed dividend | (113,932) | (42,308) | (157,949) | (68,388) |
| Deemed dividend | (1,229) | (43,753) | (1,229) | (43,753) |
| Comprehensive loss attributable to common stockholders | $(115,161) | $(86,061) | $(159,178) | $(112,141) |
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
| Preferred Stock · Common Stock · Additional · Accumulated Other · Accumulated · Treasury Stock · Noncontrolling · Stockholders’ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Paid-in Capital | Comprehensive Loss | Deficit | Shares | Amount | Interest | Equity (Deficit) | |
| Balance, December 31, 2025 | 34,057 | $1 | 8,491 | $1 | $796,721 | $(5,803) | $(921,786) | 1,458 | $(76,915) | $(3,971) | $(211,752) |
| Acquisition of controlling interest in Vivasor | — | — | — | — | — | — | — | — | — | 1,500 | 1,500 |
| Stock dividend declared in 2024, and canceled in February 2026 | (5,000) | (1) | — | — | 1 | — | — | — | — | — | — |
| Vivasor - secondary purchase | — | — | — | — | (1,050) | — | — | — | — | — | (1,050) |
| Stock-based compensation | — | — | — | — | 3,629 | — | — | — | — | — | 3,629 |
| Other comprehensive loss | — | — | — | — | — | (747) | — | — | — | — | (747) |
| Net loss | — | — | — | — | — | — | (43,270) | — | — | (2,380) | (45,650) |
| Balance, March 31, 2026 | 29,057 | — | 8,491 | $1 | $799,301 | $(6,550) | $(965,056) | 1,458 | $(76,915) | $(4,851) | $(254,070) |
| Shares issued under ESPP | — | — | 2 | — | 21 | — | — | — | — | — | 21 |
| Vivasor - repurchase of shares | — | — | — | — | (1,977) | — | — | — | — | — | (1,977) |
| Vivasor - stock-based compensation warrants | — | — | — | — | 1,164 | — | — | — | — | — | 1,164 |
| Vivasor - shares issued to Datavault | — | — | — | — | 56,197 | — | — | — | — | — | 56,197 |
| Semnur dividend distribution | — | — | — | — | (4,171) | — | — | — | — | 4,171 | — |
| Stock-based compensation | — | — | — | — | 3,595 | — | — | — | — | — | 3,595 |
| Other comprehensive loss | — | — | — | — | — | (432) | — | — | — | — | (432) |
| Net loss | — | — | — | — | — | — | (113,500) | — | — | (1,486) | (114,986) |
| Balance, June 30, 2026 | 29,057 | $— | 8,493 | $1 | $854,130 | $(6,982) | $(1,078,556) | 1,458 | $(76,915) | $(2,166) | $(310,488) |
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
| Preferred Stock · Common Stock · Additional · Accumulated Other · Accumulated · Treasury Stock · Noncontrolling · Stockholders’ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Paid-in Capital | Comprehensive Income | Deficit | Shares | Amount | Interest | Deficit | |
| Balance, December 31, 2024 | 34,057 | $1 | 6,952 | $1 | $454,614 | $6,317 | $(563,052) | 1,716 | $(90,522) | $— | $(192,641) |
| Treasury Stock transferred to Tranche B Investors for Tranche B Notes deferral | — | — | — | — | (5,353) | — | — | (143) | 7,535 | — | 2,182 |
| Treasury Stock paid for Gloperba Ex-US License | — | — | — | — | (808) | — | — | (22) | 1,174 | — | 366 |
| Treasury Stock transferred to Oramed for the Oramed Note maturity extension | — | — | — | — | (3,523) | — | — | (93) | 4,898 | — | 1,375 |
| Stock-based compensation | — | — | — | — | 3,314 | — | — | — | — | — | 3,314 |
| Net loss | — | — | — | — | — | — | (26,080) | — | — | — | (26,080) |
| Balance, March 31, 2025 | 34,057 | 1 | 6,952 | 1 | 448,244 | 6,317 | (589,132) | 1,458 | (76,915) | — | (211,484) |
| Payments in lieu of fractional shares or Reverse Stock Split | — | — | — | — | (1) | — | — | — | — | — | (1) |
| Shares issued under ESPP | — | — | 4 | — | 17 | — | — | — | — | — | 17 |
| Acquisition of controlling interest in Scilex Bio | — | — | — | — | 1,510 | — | — | — | — | 1,740 | 3,250 |
| Stock-based compensation | — | — | — | — | 3,279 | — | — | — | — | — | 3,279 |
| Net loss | — | — | — | — | — | — | (42,308) | — | — | (1,740) | (44,048) |
| Balance, June 30, 2025 | 34,057 | $1 | 6,956 | $1 | $453,049 | $6,317 | $(631,440) | 1,458 | $(76,915) | $— | $(248,987) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.